Overview

Oxaliplatin in Rectal Cancer

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

- Phase I: To determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study - Phase II: To determine the treatment efficacy according to response rates from phase I.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Oxaliplatin